德尔戈西提尼布20毫克/克奶油:慢性手湿疹的审查
Aisling McGuigan1, Matt Shirley2
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Drugs
|July 14, 2025
概括
德尔戈西提尼布20毫克/克奶油是一种适度至重度慢性手湿疹 (CHE) 的新局部治疗方法. 这种非类固醇治疗为患有CHE的成年人提供了更好的疗效和耐受性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性手湿疹 (CHE) 是一种影响成人的衰弱性疾病.
- 局部皮质类固醇往往不足或不适合中度至重度的CHE.
- 需要有效的非类固醇局部治疗CHE.
研究的目的:
- 评估delgocitinib 20 mg/g奶油对中度至重度CHE的疗效和安全性.
- 为了比较delgocitinib 20 mg/g奶油与口服阿利特雷蒂诺因在严重的CHE.
- 评估delgocitinib 20 mg/g奶油的长期疗效和安全性.
主要方法:
- 两个16周,双盲,车辆控制,跨国III期试验.
- 一项为期36周的开放式延伸研究.
- 一个主动对照试验比较delgocitinib奶油与口服阿利特雷蒂诺因.
主要成果:
- 德尔戈西提尼布20毫克/克奶油显著改善了CHE的体征和症状以及与健康有关的生活质量.
- 在开放式扩展研究期间,有效性保持不变.
- 与口服阿利特雷蒂诺因相比,德尔戈西提尼布奶油在严重的CHE中表现出更高的疗效和更好的耐受性.
结论:
- 德尔戈西提尼布20毫克/克奶油是一种有效且耐受良好的治疗方法,用于中度至重度的成人CHE.
- 它是欧盟批准用于CHE的第一个局部非类固醇疗法.
- 为CHE患者提供了一种有价值的新治疗选择,CHE患者的局部皮质类固醇治疗不充分.
相关概念视频
01:23Hand hygiene
4.2K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
4.2K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
237
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
237
01:29Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239